Cancer · Austria
Acute myeloid leukaemia
How is it diagnosed today? Your family doctor usually arranges an urgent blood test, and may send you to a hospital specialist or straight to hospital. NHS
What do you need help with?
- Join a trialStudies open to new patients in your country, and abroad if you want.13 open trials in Austria
- Offer tissue or dataGive a sample or your health data to research.
- Get supportPatient groups, money and work, help for family.
- Access and costGetting a treatment that is not on offer here, and who pays.
- Questions for your doctorReady lists to print or copy before your next visit.
- Don't pay for thisOffers with no proof in people, and what to check first.
Where treatment stands
Four steps, from proven to unproven.
Approved in Austria
Usual treatment: Intensive chemo, sometimes a stem cell transplant. NHS
15 medicines are approved for this disease in Austria:
Show all 15
- Arsenic trioxide (Trisenox, Arsenic trioxide Accord, Arsenic trioxide medac) – approved in 2002
- Azacitidine (Onureg, Azacitidine Mylan, Azacitidine Kabi) – approved in 2008
- Cedazuridine and decitabine (Inaqovi, Inqovi) – approved in 2023
- Daunorubicin and cytarabine (Vyxeos liposomal, Vyxeos) – approved in 2018
- Decitabine (Dacogen, Decitabin Sandoz) – approved in 2012
- Gemtuzumab ozogamicin (Mylotarg) – approved in 2018
- Gilteritinib (Xospata) – approved in 2019
- Glasdegib (Daurismo) – approved in 2020
- Histamine dihydrochloride (Ceplene) – approved in 2008
- Ivosidenib (Tibsovo) – approved in 2023
- Melphalan (Phelinun) – approved in 2020
- Midostaurin (Rydapt) – approved in 2017
- Quizartinib (Vanflyta) – approved in 2023
- Venetoclax (Venclyxto, Venclexta) – approved in 2016
- Posaconazole (Noxafil, Posaconazole Accord, Posaconazole AHCL) – approved in 2005
An EU approval is valid in Austria. We did not check the national approvals in Austria, so some medicines under “Approved elsewhere” may be approved here too. We did not check whether they are sold or paid for there. Checked in the regulators' own texts on 11 Nov 2026.
Approved elsewhere (17)
- Cyclophosphamide (Frindovyx) – approved for it in the US
- Cytarabine (Cytarabine, Aracytine, Cytarabine Sandoz) – approved for it in the US and France
- Daunorubicin (Daunorubicin Hydrochloride, Daunoblastin, Cerubidine) – approved for it in the US, Switzerland, and France
- Doxorubicin (Doxorubicin Hydrochloride) – approved for it in the US
- Enasidenib (Idhifa) – approved for it in the US
- Etoposide (Celltop, Etopophos) – approved for it in France
- Filgrastim (Neupogen) – approved for it in the US
- Idarubicin (Zavedos, Idamycin PFS, Idarubicine Accord) – approved for it in the US and France
- Mercaptopurine (Purinethol) – approved for it in France
- Mitoxantrone (mitoXANTRONE) – approved for it in the US
- Olutasidenib (Rezlidhia) – approved for it in the US
- Revumenib (Revuforj) – approved for it in the US
- Sargramostim (Leukine) – approved for it in the US
- Thioguanine (Tabloid, Lanvis) – approved for it in the US and France
- Treosulfan (Grafapex) – approved for it in the US
- Tretinoin (Tretinoin, Vesanoid) – approved for it in the US, Switzerland, and France
- Ziftomenib (Komzifti) – approved for it in the US
Being tested in people
13 open trials in Austria, 628 worldwide. See the trials
- 4 chemotherapy blocks: Course 1 AIE (cytarabine/idarubicin/etoposide), Course 2 AI (cytarabine/idarubicin), Course 3 HAD (high-dose cytarabine (1g)/daunorubicin), Course 4 HA (high-dose cytarabine). (Phase 3)
- AG-120 (Phase 3)
- AG-221 (Phase 3)
- all-trans retinoic acid (ATRA) (Phase 3)
Only in the lab or in animals
Of the 20 newest articles, 2 were in animals and 1 in the lab. See them
No proof it works
Animal worm medicines (ivermectin, fenbendazole) for cancer: not approved, and not enough research in people to know if they help. American Cancer Society: What to Know About Ivermectin (21 May 2026) · American Cancer Society: What to Know About Fenbendazole (21 Oct 2025)
Join a trial
Studies that are taking new patients in Austria. The trial team decides who can join. Change the country at the top.
Phase 1: first tests in people · Phase 2: does it help? · Phase 3: compared with the usual treatment
2 open trials in Austria with these filters
Tests ziftomenib with chemotherapy in children with relapsed acute leukemia
NCT06376162 · ClinicalTrials.gov
- Vienna – St. Anna Kinderspital GmbH
Ages 0 to 21
Contact the trial teamRevumenib plus chemotherapy for children with relapsed or resistant acute myeloid leukemia
2025-521390-14-00 · EU Clinical Trials Register
- Vienna – St. Anna Kinderspital GmbH
Up to age 64
Contact the trial team
Available abroad (240 trials)
Nearest region first. Travel and treatment abroad are often not paid for; ask your health insurer first.
Tests ponatinib in children with hard-to-treat leukemias, lymphomas or solid tumors
NCT03934372 · ClinicalTrials.gov
Countries: Belgium, Spain, France and 4 more
- Ghent, Belgium – Ghent university hospital
- Barcelona, Spain – Hospital General Universitario Vall D Hebron
- Barcelona, Spain – Hospital Sant Joan de Deu de Manresa
Ages 1 to 17
Contact the trial teamStudy of how the body absorbs ziftomenib in relapsed or hard-to-treat AML or MDS
NCT07929740 · ClinicalTrials.gov
Countries: Spain, France, Italy
- Barcelona, Spain – Hospital Clinic de Barcelona
- Madrid, Spain – MD Anderson Cancer Center
- Oviedo, Spain – Hospital Universitario Central De Asturias
Age 18 and over
Contact the trial teamTesting CHM-029 pill in adults with relapsed or hard-to-treat acute myeloid leukemia
NCT07751991 · ClinicalTrials.gov
Countries: Germany, Spain, United Kingdom and 3 more
- Berlin, Germany – Charite Universitaetsmedizin Berlin KöR
- Cáceres, Spain – Hospital San Pedro De Alcántara
- Madrid, Spain – Hospital Universitario Fundación Jiménez Díaz
Age 18 and over
Contact the trial teamTesting JNJ-95804306 in Blood Cancers That Returned or Did Not Respond to Treatment
2026-525234-39-00 · EU Clinical Trials Register
Countries: Belgium, Germany, Denmark and 2 more
- Edegem, Belgium – Universitair Ziekenhuis Antwerpen
- Leuven, Belgium – UZ Leuven
- Berlin, Germany – Charite Universitaetsmedizin Berlin KöR
No age limit given in the registry
Contact the trial teamFirst test of GEN3018 in adults with returned or resistant acute myeloid leukemia
NCT07384715 · ClinicalTrials.gov
Countries: Spain, Italy, Netherlands
- Barcelona, Spain – Hospital Clinic de Barcelona
- Barcelona, Spain – Hospital Universitari Vall d'Hebron
- Madrid, Spain – Hospital Universitario 12 de Octubre
Age 18 and over
Contact the trial teamTests REM-422 in adults with relapsed or hard-to-treat AML or higher-risk MDS
NCT06297941 · ClinicalTrials.gov
Countries: France, United States
- Bordeaux, France – Centre Hospitalier Universitaire (CHU) de Bordeaux
- Paris, France – AP-HP Hôpital Saint Louis
- Toulouse, France – IUCT Oncopôle
Age 18 and over
Contact the trial teamTests APL-4098 alone and with other drugs in adults with blood cancers
NCT06372717 · ClinicalTrials.gov
Countries: United Kingdom, Australia
- Cardiff, United Kingdom – University Hospital of Wales
- Glasgow, United Kingdom – Beatson West of Scotland Cancer Centre
- London, United Kingdom – Sarah Cannon Research Institute UK
Age 18 and over
Contact the trial teamCompares intensive and gentler treatments for relapsed acute myeloid leukemia
NCT06713837 · ClinicalTrials.gov
Countries: Czechia, Germany, Spain and 3 more
- Brno, Czechia – Fakultni nemocnice Brno
- Novy Hradec Kralove, Czechia – Fakultni Nemocnice Hradec Kralove
- Olomouc, Czechia – University Hospital Olomouc
Age 18 and over
Contact the trial teamObserves outcomes in people with relapsed or refractory acute myeloid leukemia
NCT06459024 · ClinicalTrials.gov
Countries: Germany, Spain, Italy and 4 more
- Aachen, Germany – University Hospital Aachen
- Greifswald, Germany – University Hospital Greifswald
- Halle, Germany – University Hospital Halle
Age 6 and over
Contact the trial teamTests eganelisib alone and with other drugs in blood cancers
NCT06533761 · ClinicalTrials.gov
Countries: Spain, United States
- Cáceres, Spain – Hospital San Pedro De Alcántara
- Valencia, Spain – Hospital Universitario Y Politecnico La Fe
- Aurora, United States – Anshutz Cancer Pavilion
Age 18 and over
Contact the trial teamTesting AUTX-703 in adults with relapsed or hard-to-treat leukemia or myelodysplastic syndromes
NCT06846606 · ClinicalTrials.gov
Countries: France, United States
- Villejuif, France – Institut Gustave Roussy
- Buffalo, United States – Roswell Park Comprehensive Cancer Center
- Chapel Hill, United States – University of North Carolina at Chapel Hill
Age 18 and over
Contact the trial teamCAR-cell infusion for leukemia and BPDCN that returned or did not respond
NCT07877610 · ClinicalTrials.gov
Countries: Italy
- Bergamo, Italy – Asst Papa Giovanni XXIII
- Monza, Italy – Fondazione IRCCS San Gerardo dei Tintori
Ages 0 to 75
Contact the trial teamTests revumenib in people with relapsed or hard-to-treat acute leukemia
NCT04065399 · ClinicalTrials.gov
Countries: Germany, Spain, France and 7 more
- Hamburg, Germany – University Medical Center Hamburg-Eppendorf
- Leipzig, Germany – Universitaet Leipzig
- Mainz, Germany – Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR
Age 0 and over
Contact the trial teamTests LB-208 in adults whose leukemia or myelodysplastic syndrome returned or resisted treatment
2025-523396-38-00 · EU Clinical Trials Register
Countries: Spain
- Barcelona, Spain – Hospital Universitari Vall d'Hebron
- Cáceres, Spain – Hospital San Pedro De Alcántara
- Madrid, Spain – Hospital General Universitario Gregorio Marañón
Age 18 and over
Contact the trial teamPivekimab sunirine for children with acute myeloid leukemia that returned or did not respond
NCT07306832 · ClinicalTrials.gov
Countries: France, United Kingdom, Italy and 4 more
- Bordeaux, France – Chu Bordeaux - Hopital Pellegrin
- Paris, France – Hopital Armand Trousseau
- Cambridge, United Kingdom – Cambridge University Hospital
Ages 0 to 17
Contact the trial teamTests trametinib and gilteritinib in adults with relapsed or hard-to-treat acute leukemia
2024-518301-18-00 · EU Clinical Trials Register
Countries: Poland
- Gdansk, Poland – Uniwersyteckie Centrum Kliniczne
- Warsaw, Poland – Instytut Hematologii I Transfuzjologii
Age 18 and over
Contact the trial teamTests modified T cells with an antibody bridge in adults with acute myeloid leukemia
NCT05949125 · ClinicalTrials.gov
Countries: Germany, Netherlands
- Berlin, Germany – Charite Universitaetsmedizin Berlin KöR
- Dresden, Germany – Technische Universität Dresden
- Essen, Germany – Universitaetsklinikum Essen (AoR)
Age 18 and over
Contact the trial teamTests RVU120 with venetoclax in adults with relapsed or refractory acute myeloid leukemia
NCT06191263 · ClinicalTrials.gov
Countries: Spain, France, Italy and 1 more
- Barcelona, Spain – Institut Catala d'Oncologia
- Barcelona, Spain – Hospital del Mar
- Barcelona, Spain – Hospital de la Santa Creu i Sant Pau
Age 18 and over
Contact the trial teamTesting ziftomenib combinations in relapsed acute myeloid leukemia
NCT06001788 · ClinicalTrials.gov
Countries: Germany, Spain, Italy and 1 more
- Hanover, Germany – Medizinische Hochschule Hannover
- Barcelona, Spain – Hospital Universitari Vall d'Hebron
- Oviedo, Spain – Hospital Universitario Central De Asturias
Age 18 and over
Contact the trial teamAdding hydroxyurea to combination treatment for returned or resistant acute myeloid leukemia
NCT07766850 · ClinicalTrials.gov
Countries: Sweden
- Stockholm, Sweden – Medical Unit Hematology, Karolinska University Hospital
Ages 18 to 74
Contact the trial teamTests liposomal annamycin with cytarabine for returning acute myeloid leukemia
NCT06788756 · ClinicalTrials.gov
Countries: Belgium, Czechia, Spain and 8 more
- Anderlecht, Belgium – Institut Jules Bordet
- Hradec Králové, Czechia – Fakultni nemocnice Hradec Kralove
- Badalona, Spain – Institut Catala d'Oncologia
Ages 18 to 80
Contact the trial teamCARCIK-CD123/33 cell therapy for relapsed or resistant acute myeloid leukemia and BPDCN
2025-524977-18-00 · EU Clinical Trials Register
Countries: Italy
- Bergamo, Italy – Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII
- Monza, Italy – Fondazione IRCCS San Gerardo dei Tintori
No age limit given in the registry
Contact the trial teamPivekimab Sunirine for Children and Teens With Acute Myeloid Leukemia That Returned
2024-520125-36-00 · EU Clinical Trials Register
Countries: Czechia, Spain, France and 2 more
- Prague, Czechia – Fakultni Nemocnice Motol a Homolka
- Esplugues de Llobregat, Spain – Hospital Sant Joan De Deu Barcelona
- Madrid, Spain – Hospital Infantil Universitario Nino Jesus
Up to age 17
Contact the trial teamTests adding hydroxyurea to salvage chemotherapy for returning or resistant acute myeloid leukemia
2026-526961-76-00 · EU Clinical Trials Register
Countries: Sweden
- Huddinge, Sweden – Karolinska University Hospital
- Uppsala, Sweden – Uppsala University Hospital
Age 18 and over
Contact the trial teamTests AG-120 pill in advanced blood cancers with an IDH1 gene change
NCT02074839 · ClinicalTrials.gov
Countries: France, United States
- Marseille, France – Hôpital la Timone
- Pessac, France – Hopital Haut-Leveque
- Pierre-Bénite, France – Central Lyon Sud
Age 18 and over
Contact the trial teamActinomycin D with venetoclax for acute myeloid leukemia that returned or did not respond
2025-524728-22-01 · EU Clinical Trials Register
Countries: France
- Marseille, France – Institut Paoli-Calmettes
- Nice, France – Centre Hospitalier Universitaire de Nice
- Paris, France – Assistance Publique Hopitaux de Paris
Age 18 and over
Contact the trial teamTests CART84 cell infusion in adults with relapsed or refractory leukemia
2024-519966-31-00 · EU Clinical Trials Register
Countries: Spain
- Barcelona, Spain – Hospital Clinic de Barcelona
- Valencia, Spain – Hospital Universitario Y Politecnico La Fe
Age 18 and over
Contact the trial teamTests modified immune cells in adults with relapsed or hard-to-treat acute myeloid leukemia
NCT06424340 · ClinicalTrials.gov
Countries: Netherlands
- Leiden, Netherlands – Leiden University Medical Center
Age 18 and over
Contact the trial teamTests eltanexor in adults with returning NPM1-mutated acute myeloid leukemia
2024-514724-16-01 · EU Clinical Trials Register
Countries: Italy
- Ancona, Italy – Azienda Ospedaliero-Universitaria delle Marche
- Catania, Italy – Azienda Ospedaliero-Universitaria Policlinico G. Rodolico-San Marco Di Catania
Age 18 and over
Contact the trial teamTests MB-dNPM-1-TCR.1 in adults with relapsed or refractory acute myeloid leukemia
2023-505806-41-00 · EU Clinical Trials Register
Countries: Netherlands
- Leiden, Netherlands – Academisch Ziekenhuis Leiden
Age 18 and over
Contact the trial teamTests ABD-3001 safety in adults with relapsed or hard-to-treat blood cancer
2024-518813-24-00 · EU Clinical Trials Register
Countries: France
- Marseille, France – Centre Hospitalier Regional De Marseille
- Nice, France – Centre Hospitalier Universitaire de Nice
- Paris, France – Hopital Saint Louis
Age 18 and over
Contact the trial teamTests CART84 cell therapy in adults with relapsed or refractory leukemia
NCT07471789 · ClinicalTrials.gov
Countries: Spain
- Barcelona, Spain – Hospital Clinic de Barcelona
- Valencia, Spain – Hospital Universitario Y Politecnico La Fe
Age 18 and over
Contact the trial teamQuality-of-life-guided blood transfusions in advanced myelodysplastic syndromes or acute myeloid leukemia
NCT07328191 · ClinicalTrials.gov
Countries: France
- Nice, France – CHU de Nice
Age 18 and over
Contact the trial teamTests donor immune cells to prevent graft-versus-host disease in children with leukemia
NCT07366801 · ClinicalTrials.gov
Countries: Russia
- Moscow, Russia – National medical research center of pediatric haematology, oncology and immulogy named after Dmytriy Rogachyov, Moscow, 117198
Ages 1 to 25
Contact the trial teamTests CD19 CAR-T cells in adults with relapsed leukemia that expresses CD19
NCT06649227 · ClinicalTrials.gov
Countries: France
- Lille, France – CHU de Lille
Age 18 and over
Contact the trial teamDonor immune cell infusions with stem cell transplant for acute leukemia
NCT07256210 · ClinicalTrials.gov
Countries: Russia
- Moscow, Russia – Dmitry Rogachev Federal Research and Clinical Centre of Paediatric Haematology, Oncology and Immunology
Ages 0 to 25
Contact the trial teamTests AB8939 in adults with relapsed or refractory acute myeloid leukemia
NCT05211570 · ClinicalTrials.gov
Countries: Germany, Spain, France and 2 more
- Chemnitz, Germany – Klinikum Chemnitz gGmbH
- Leipzig, Germany – Universitaet Leipzig
- Alicante, Spain – Hospital General Universitario Dr. Balmis
Age 18 and over
The registry has not updated this record for a long time. Ask the team whether it is still open.
Contact the trial teamTests CCTx-001 cell therapy in adults with relapsed or refractory acute myeloid leukemia
NCT06281847 · ClinicalTrials.gov
Countries: Germany, Spain, France and 1 more
- Munich, Germany – Ludwig-Maximilians University of Munich
- Ulm, Germany – University Hospital Ulm
- Barcelona, Spain – Vall d'Hebron University Hospital
Age 18 and over
The registry has not updated this record for a long time. Ask the team whether it is still open.
Contact the trial teamTests tuspetinib in adults with relapsed or refractory acute myeloid leukemia
NCT03850574 · ClinicalTrials.gov
Countries: Germany, Spain, Poland and 5 more
- Berlin, Germany – Charite Universitaetsmedizin Berlin KöR
- Leipzig, Germany – University of Leipzig
- Alicante, Spain – Hospital General Universitario de Alicante
Age 18 and over
The registry has not updated this record for a long time. Ask the team whether it is still open.
Contact the trial teamStudies immune factors in acute myeloid leukemia that returns after stem cell transplant
NCT05124288 · ClinicalTrials.gov
Countries: Italy
- Milan, Italy – IRCCS Ospedale San Raffaele
Age 18 and over
The registry has not updated this record for a long time. Ask the team whether it is still open.
Contact the trial team
Showing 40 of 240. Use the filters to narrow the list.
How to get into an early trial
- A lab does not treat patients, so you cannot phone the lab to get a new treatment.
- Ask your doctor to look at phase 1 trials with you. These are the first tests in people.
- If one fits, your doctor sends a referral to the trial centre.
- The trial team checks whether you can join and decides.
Trial data: ClinicalTrials.gov, courtesy of the U.S. National Library of Medicine; it does not endorse this site. EU trials: EU Clinical Trials Information System (CTIS), European Medicines Agency. We show the registry records; the trial team has the last word on who can join.
Latest research
The five newest articles. The label comes from the PubMed index: whether it was tested in people, in animals or only in the lab.
- Gemtuzumab Ozogamicin for Patients with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia: A French Retrospective Observational Study.EJHaem · 2026-11-14
- Elevated Allele Frequency of a Common Germline PDCD1 Variant Associated with Leukocytosis and Thrombocytopenia in Acute Myeloid Leukemia Treated with HDCT/ASCT.Cancers (Basel) · 2026-11-03
- ReviewGenetic and nongenetic mechanisms of menin inhibitor resistance in acute leukemia.Int J Hematol · 2026-11-14
- ReviewAcute myeloid leukemia with TP53 mutation: molecular mechanisms and therapeutic advances.Leuk Lymphoma · 2026-11-13
- In the labSystematic Characterization of AML Cell Lines to Support Preclinical In Vitro CAR-T Research.Cells · 2026-10-28
Is it true?
Saw something on social media? Fact-check it now.
Get screened
For family members and people at higher risk: free checks can find some cancers early, before there are symptoms.
There is no routine screening for this cancer. If you have symptoms or a family history, talk to your doctor.
If several people in your family had cancer, ask your GP whether genetic counselling makes sense for you.
Offer tissue or data
You can help research move faster.
Give tissue or blood to research
Before an operation or a blood test, ask if left-over tissue or blood can go to a biobank.
- Does this hospital have a biobank?
- What will the sample be used for, and for how long?
- Can I change my mind later?
Share your health data
Ask your doctor whether there is a patient registry for your illness. You choose what you share.
Take part as a healthy volunteer
Some studies need people without the illness, often family members.
Volunteer studiesGet support
Patient groups in Austria
- Österreichische Krebshilfe
Free, anonymous counselling at regional centres in every federal state, psycho-oncology and emergency financial aid.
Phone: 01 7966450
Help for every illness in Austria (4)
- 1450 – Rund-um-die-Uhr-Gesundheitsberatung
Austria's nationwide 24/7 telephone health advice line: trained staff assess symptoms and guide callers to the appropriate care.
- Telefonseelsorge Österreich – Notruf 142
Free, confidential 24/7 emotional support and crisis line for anyone in Austria, reachable on 142.
- Gesundheitsportal Österreich (gesundheit.gv.at)
Austria's official public health portal, offering quality-assured information on diseases, prevention, health services and patient rights.
- ARGE Selbsthilfe Österreich
ARGE Selbsthilfe Österreich represents the interests of self-help groups and patient organisations in Austrian social and health policy.
Available abroad: international groups (8)
- DKMS
Finds blood stem cell donors worldwide so that people with blood cancer can have a transplant.
- Acute Leukemia Advocates Network (ALAN)
Global network of 69 acute leukaemia patient organisations (hosted by the Swiss Leukemia Patient Advocates Foundation); member list helps patients find a national group.
- European Cancer Patient Coalition (ECPC)
Umbrella of European cancer patient groups, with a patient toolbox and a legal network for cancer patients.
- European Reference Networks (European Commission)
The European Commission's 24 expert networks for rare and complex diseases; your doctor can contact them.
- EURORDIS – Rare Diseases Europe
Alliance of over 1,000 rare disease patient organisations, with a list of rare disease helplines by country.
- Workgroup of European Cancer Patient Advocacy Networks
Network of pan-European cancer patient umbrella groups (including the blood cancer networks): joint advocacy, WECAN Academy training for patient advocates, patient experience data courses.
- European Patients' Forum (EPF)
Umbrella of European patient organisations and national patient coalitions.
- International Alliance of Patients' Organizations
Global alliance of patient organisations of all diseases, promoting patient-centred healthcare.
Money and work
If the illness stops you working, ask the hospital social worker which benefits you can claim.
- Which sick-pay or disability benefits can I apply for?
- Is there help for the carer in the family?
- Are travel costs to treatment paid back?
After a loss
If someone you love has died, you do not have to go through it alone. Many families ask themselves whether they missed something; the care team can talk this through with you.
We have no grief support group in Austria in our list yet. The hospital's social worker or palliative team can tell you where to find one.
Hospitals and hospices have chaplains and counsellors, for any faith or none.
Some families decide to give tissue to research after death, so that the illness can be studied. If you want to, ask the treating hospital early whether it has such a programme.
Access and cost
- If no trial fits, your doctor can ask the company and the medicines authority whether early access (compassionate use) is possible.
- In Austria the medicines agency BASG lists the early-access programmes that are running. BASG (Austria): list of compassionate use programmes, no. 054
- In the EU you may get planned care in another EU country. Ask your health insurer before you go. Your Europe: planned medical treatment abroad
- Some medicines for this disease are approved abroad but maybe not here: see “Approved elsewhere” under “Approved in Austria” above.
Don't pay for this
No one will cure you through a Facebook message or ask you to invest money.
- Animal worm medicines bought online (ivermectin, fenbendazole)
They are made for animals and not tested for cancer in people. High doses can cause seizures or coma, fenbendazole has caused liver damage, they may weaken your cancer treatment, and they can keep you out of a trial.
American Cancer Society: What to Know About Ivermectin (21 May 2026) · American Cancer Society: What to Know About Fenbendazole (21 Oct 2025) · ASCO: Oncologists urged to discuss ivermectin and fenbendazole (17 Jun 2026)
- “Treatment plans” offered in comments
Ask which published study in people is behind it. Usually there is none.
- Anyone who answers your post with a private treatment
Real trials are listed in a public registry. Check the number on ClinicalTrials.gov or the EU trial register.
- Strangers offering investments or “funds” for treatment
Do not reply and do not send money. Report the comment or message.
Before you pay for anything, ask three things
- Can I have a written price, with everything that is included?
- Which published study in people shows it helps my disease?
- What does my doctor say about it?
Questions for your doctor
Ready lists for a new diagnosis, during treatment, before a trial and before you pay. Open the question lists
Not medical advice. We show what is open and what is known; your care team decides what fits you.